Ascentage Pharma (NASDAQ:AAPG) shares were in focus on Tuesday, January 6, 2026, following the announcement that the U.S. FDA has cleared its Investigational New Drug (IND) application for APG-3288.
HUTCHMED (China) Limited (NASDAQ:HCM) shares climbed in after-hours trading Wednesday after the company announced that its novel Syk inhibitor, sovleplenib, met the primary endpoint in the Phase III registration portion of the ESLIM-02 trial.
Marvell Technology said on Tuesday it will buy networking equipment provider XConn Technologies in a deal worth about $540 million, as the chipmaker doubles down on data center hardware amid a race to expand artificial intelligence infrastructure.
Johnson & Johnson (NYSE:JNJ) announced on Tuesday, January 6, 2026, that its Phase 2b JASMINE study of nipocalimab in adults with moderate-to-severe systemic lupus erythematosus (SLE) met its primary and key secondary endpoints.
Zai Lab Limited (NASDAQ:ZLAB) announced on January 6, 2026, that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib).
This approval targets adult patients with advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).
This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.
Alumis (NASDAQ:ALMS) surged as much as 82% in early trading Tuesday after its experimental oral drug, envudeucitinib, outperformed both a placebo and Amgen’s blockbuster Otezla in two Phase 3 trials for moderate-to-severe plaque psoriasis.
Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.
Cognition Therapeutics (NASDAQ:CGTX) announced on January 6, 2026, the publication of peer-reviewed results from its Phase 2 SHIMMER study in the journal Alzheimer's & Dementia.
Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.
The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).
Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.
The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.
Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.
